Sagimet Biosciences (SGMT) Competitors $8.68 +0.43 (+5.21%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$8.80 +0.13 (+1.44%) As of 09:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMT vs. COLL, AKBA, SYRE, MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, and PRAXShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Its Competitors Collegium Pharmaceutical Akebia Therapeutics Spyre Therapeutics Mineralys Therapeutics Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Ardelyx Oric Pharmaceuticals Praxis Precision Medicines Collegium Pharmaceutical (NASDAQ:COLL) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability. Which has more volatility and risk, COLL or SGMT? Collegium Pharmaceutical has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.35, suggesting that its share price is 235% more volatile than the S&P 500. Which has preferable earnings and valuation, COLL or SGMT? Collegium Pharmaceutical has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$631.45M1.57$69.19M$1.2225.33Sagimet Biosciences$2M133.11-$45.57M-$1.76-4.93 Does the media favor COLL or SGMT? In the previous week, Collegium Pharmaceutical had 8 more articles in the media than Sagimet Biosciences. MarketBeat recorded 8 mentions for Collegium Pharmaceutical and 0 mentions for Sagimet Biosciences. Collegium Pharmaceutical's average media sentiment score of 0.66 beat Sagimet Biosciences' score of 0.51 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Overall Sentiment Collegium Pharmaceutical Positive Sagimet Biosciences Positive Do analysts prefer COLL or SGMT? Collegium Pharmaceutical currently has a consensus target price of $43.75, suggesting a potential upside of 41.59%. Sagimet Biosciences has a consensus target price of $26.60, suggesting a potential upside of 206.45%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Sagimet Biosciences 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in COLL or SGMT? 87.9% of Sagimet Biosciences shares are held by institutional investors. 2.5% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is COLL or SGMT more profitable? Collegium Pharmaceutical has a net margin of 6.61% compared to Sagimet Biosciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 99.08% beat Sagimet Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical6.61% 99.08% 15.14% Sagimet Biosciences N/A -35.21%-34.09% SummaryCollegium Pharmaceutical beats Sagimet Biosciences on 9 of the 16 factors compared between the two stocks. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.07M$2.91B$5.51B$9.02BDividend YieldN/A2.44%5.24%4.05%P/E Ratio-4.9320.4427.2120.09Price / Sales133.11190.28370.4792.99Price / CashN/A41.7026.2128.59Price / Book1.717.397.945.55Net Income-$45.57M-$55.04M$3.17B$248.49M7 Day Performance8.09%2.51%1.79%4.87%1 Month Performance56.12%-0.21%1.27%6.63%1 Year Performance179.10%3.41%33.56%20.38% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences2.3942 of 5 stars$8.68+5.2%$26.60+206.5%+193.2%$253.07M$2M-4.938COLLCollegium Pharmaceutical4.2597 of 5 stars$29.57-1.2%$43.75+48.0%-4.0%$961.71M$631.45M24.24210News CoverageAnalyst DowngradeBuyback AnnouncementGap UpAKBAAkebia Therapeutics4.2343 of 5 stars$3.64-0.3%$6.75+85.4%+287.9%$958.62M$160.18M-17.33430SYRESpyre Therapeutics1.3354 of 5 stars$14.97-1.6%$53.40+256.7%-40.0%$917.39M$890K-3.9773MLYSMineralys Therapeutics2.1338 of 5 stars$13.53-1.3%$32.25+138.4%+8.8%$893.55MN/A-3.6328AVDLAvadel Pharmaceuticals2.435 of 5 stars$8.85-3.8%$18.17+105.3%-39.9%$890M$169.12M-32.7870PHVSPharvaris1.7646 of 5 stars$17.60+3.5%$36.20+105.7%+8.1%$888.93MN/A-5.8530NRIXNurix Therapeutics1.6053 of 5 stars$11.39-2.1%$30.18+164.9%-36.5%$887.38M$54.55M-4.07300Upcoming EarningsARDXArdelyx4.4322 of 5 stars$3.92+6.2%$10.89+177.8%-17.8%$882.85M$333.61M-17.8290ORICOric Pharmaceuticals4.6225 of 5 stars$10.15-1.6%$19.17+88.8%+38.5%$878.66MN/A-5.4380PRAXPraxis Precision Medicines2.9381 of 5 stars$42.05-2.2%$109.90+161.4%+15.8%$875.87M$8.55M-3.92110 Related Companies and Tools Related Companies Collegium Pharmaceutical Competitors Akebia Therapeutics Competitors Spyre Therapeutics Competitors Mineralys Therapeutics Competitors Avadel Pharmaceuticals Competitors Pharvaris Competitors Nurix Therapeutics Competitors Ardelyx Competitors Oric Pharmaceuticals Competitors Praxis Precision Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMT) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SGMT Stock Alerts